peripheral blood biomarkers associated with clinical outcome in non–small cell lung cancer patients treated with nivolumab

Objective the aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with nsclc treated with nivolumab. methods univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent nsclc treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absolute neutrophil count (anc), absolute lymphocyte count (alc), absolute monocyte count, and absolute eosinophil count (aec), as well as serum c-reactive protein and lactate dehydrogenase levels. progression-free survival, overall survival, and response rate were determined. results among the variables selected by univariable analysis, a low anc, high alc, and high aec were significantly and independently associated with both better progression-free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. a similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. conclusions a baseline signature of a low anc, high alc, and high aec was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.